Stockscreener 앱 받기
2.15
2.87%
0.06
시간 외 거래:
2.16
0.01
+0.47%
전일 마감가:
$2.09
열려 있는:
$2.06
하루 거래량:
73,645
Relative Volume:
1.15
시가총액:
$5.91M
수익:
-
순이익/손실:
$-14.11M
주가수익비율:
-0.2006
EPS:
-10.7181
순현금흐름:
$-13.60M
1주 성능:
+8.59%
1개월 성능:
-27.36%
6개월 성능:
-67.81%
1년 성능:
-66.92%
1일 변동 폭
$2.06
$2.2799
1주일 범위
$1.98
$2.48
52주 변동 폭
$1.76
$14.24
프로세사 파마슈티컬스 Stock (PCSA) Company Profile
명칭
Processa Pharmaceuticals Inc
전화
443-776-3133
주소
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.15 | 6.08M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
프로세사 파마슈티컬스 Stock (PCSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-25 | 개시 | H.C. Wainwright | Buy |
프로세사 파마슈티컬스 주식(PCSA)의 최신 뉴스
PCSA Q4 2025 Earnings: EPS Misses Estimates by 67.97% as Pre-Revenue Biotech Faces HeadwindsWeak Earnings Momentum - newsline.com
Processa Pharmaceuticals, Inc. - MLQ.ai
PCSA Stock Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
PCSA Stock Price, Quote & Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
Processa Pharmaceuticals CAO Wendy Guy buys $4,700 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals CAO Wendy Guy buys $4,700 in stock - Investing.com
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals’ pres. David Young buys $4,590 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals chief business and strategy officer buys $4,065 in stock - Investing.com Nigeria
Processa Pharmaceuticals’ pres. David Young buys $4,590 in stock - Investing.com
Processa Pharmaceuticals (PCSA) R&D chief buys 1,786 shares at $2.57 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO adds 2,292 shares in open-market buy - Stock Titan
Processa (NASDAQ: PCSA) CEO adds 2,129 shares in open-market buy - Stock Titan
Processa (NASDAQ: PCSA) officer adds to stake with share purchase - Stock Titan
Processa (PCSA) CAO Wendy Guy adds 1,829 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Guy Wendy - Moomoo
Processa Pharmaceuticals (PCSA) Edges Lower as Biotech Volatility PersistsThe Legal Advocate - The Legal Advocate
Processa Pharmaceuticals (PCSA) Surges 5.75% as Shares Test Key Resistance LevelVolume Spike Alerts - The Legal Advocate
PCSA Q4 2025 Earnings: EPS Misses Estimates Amid Pipeline DevelopmentEarnings Decline Risk - The Legal Advocate
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical PipelineConsensus Miss Rate - newsline.com
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical Pipeline ProgressesGuidance Downgrade Alert - The Legal Advocate
Processa Pharmaceuticals CAO Wendy Guy buys $4,701 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,473 in stock - Investing.com India
Processa Pharmaceuticals president David Young buys $4,588 in shares - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,473 in stock By Investing.com - Investing.com South Africa
Sian Bigora, Processa CDO, buys $5,341 in stock - Investing.com UK
Processa Pharmaceuticals president David Young buys $4,588 in shares By Investing.com - Investing.com Australia
Processa Pharmaceuticals CAO Wendy Guy buys $4,701 in stock - Investing.com
Processa (NASDAQ: PCSA) strategy chief buys 1,369 shares in open market - Stock Titan
Processa (PCSA) CEO adds 1,843 shares and corrects prior Form 4 - Stock Titan
Processa (PCSA) R&D head buys 1,545 shares at $2.97 in open market - Stock Titan
Processa Pharmaceuticals (NASDAQ: PCSA) CAO purchases 1,583 shares and corrects prior Form 4 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO adds 1,984 shares in Form 4 buy - Stock Titan
Processa (NASDAQ: PCSA) CEO George Ng buys 1,843 shares in open market - Stock Titan
Processa Pharmaceuticals (PCSA) CDO buys 1,971 shares in open-market trade - Stock Titan
What Processa Pharmaceuticals PCSA is doing that separates it from the herd Modest Gains 20260507Viral Momentum Stocks - Newser
Processa Pharmaceuticals (PCSA) holder CVI reports 200,000-share stake, 7.0% - Stock Titan
TradingKey - TradingKey
The valuation case for Processa Pharmaceuticals (PCSA) that is hard to ignore (+4.36%) 2026-05-08Gamma Squeeze - The Legal Advocate
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Processa Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lin Patrick - Moomoo
2025 Executive Compensation, Ownership, and Governance Overview for Heatwurx, Inc. (Now Based in Vero Beach, FL) - minichart.com.sg
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
프로세사 파마슈티컬스 (PCSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
프로세사 파마슈티컬스 주식 (PCSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 15 '26 |
Buy |
2.22 |
2,654 |
5,892 |
13,412 |
| Ng George K | Chief Executive Officer |
Jun 15 '26 |
Buy |
2.22 |
2,465 |
5,472 |
12,435 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 15 '26 |
Buy |
2.22 |
1,831 |
4,065 |
11,007 |
| Guy Wendy | Chief Administrative Officer |
Jun 15 '26 |
Buy |
2.22 |
2,118 |
4,702 |
11,958 |
| Young David | Pres. Research & Development |
May 29 '26 |
Buy |
2.57 |
1,786 |
4,590 |
17,131 |
| SKIBSTED RUSSELL | Chief Financial Officer |
May 29 '26 |
Buy |
2.57 |
2,292 |
5,890 |
10,758 |
| Ng George K | Chief Executive Officer |
May 29 '26 |
Buy |
2.57 |
2,129 |
5,472 |
9,970 |
| Lin Patrick | Chief Business - Strategy Off |
May 29 '26 |
Buy |
2.57 |
1,582 |
4,066 |
9,176 |
| Guy Wendy | Chief Administrative Officer |
May 29 '26 |
Buy |
2.57 |
1,829 |
4,701 |
9,840 |
| Ng George K | Chief Executive Officer |
May 15 '26 |
Buy |
2.97 |
1,843 |
5,474 |
7,841 |
2.60%
0.94%
자본화:
|
볼륨(24시간):